

# Marie Lordkipanidze

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1157803/publications.pdf>

Version: 2024-02-01

107  
papers

3,024  
citations

218677  
26  
h-index

182427  
51  
g-index

110  
all docs

110  
docs citations

110  
times ranked

3544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. <i>Platelets</i> , 2022, 33, 298-303.	2.3	3
2	Rare missense variants in Tropomyosin-4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 478-485.	3.8	3
3	Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	2.4	12
4	Editorial: Established and Novel Roles of Platelets in Health and Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 835615.	2.4	2
5	A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMEDI-F1 study. <i>Supportive Care in Cancer</i> , 2022, 30, 3389-3399.	2.2	3
6	Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 821865.	3.4	1
7	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1443-1453.	3.4	3
8	Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e055454.	1.9	1
9	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. <i>Frontiers in Pharmacology</i> , 2022, 13, 878416.	3.5	2
10	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2127-2135.	3.8	6
11	Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use. <i>Addiction Biology</i> , 2021, 26, e12890.	2.6	17
12	Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12184.	3.7	2
13	Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 606861.	4.8	6
14	Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American Heart Association</i> , 2021, 10, e016602.	3.7	2
15	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1364-1371.	3.8	19
16	Platelet Function in Viral Immunity and SARS-CoV-2 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 419-426.	2.7	14
17	A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24080-e24080.	1.6	0
18	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. <i>Cell Reports Medicine</i> , 2021, 2, 100299.	6.5	2

#	ARTICLE	IF	CITATIONS
19	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. CJC Open, 2021, 3, 814-821.	1.5	3
20	The effect of aging on the bone healing properties of blood plasma. Injury, 2021, 52, 1697-1708.	1.7	4
21	A Meta-Analysis of the Effect of Paper Versus Digital Reading on Reading Comprehension in Health Professional Education. American Journal of Pharmaceutical Education, 2021, 85, 8525.	2.1	2
22	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	3.8	20
23	Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment. Frontiers in Cardiovascular Medicine, 2021, 8, 739045.	2.4	9
24	Differences in platelet-rich plasma composition influence bone healing. Journal of Clinical Periodontology, 2021, 48, 1613-1623.	4.9	11
25	The brain-derived neurotrophic factor prompts platelet aggregation and secretion. Blood Advances, 2021, 5, 3568-3580.	5.2	14
26	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 2021, 22, 13079.	4.1	20
27	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	1.7	12
28	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
29	Platelet count and disease – editorial policy. Platelets, 2020, 31, 969-970.	2.3	5
30	Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model. Biomolecules, 2020, 10, 1318.	4.0	8
31	Advances in Platelet Function Testing – Light Transmission Aggregometry and Beyond. Journal of Clinical Medicine, 2020, 9, 2636.	2.4	31
32	Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF. Frontiers in Immunology, 2020, 11, 575607.	4.8	31
33	Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition – Insights for Multi-Center Trials. Journal of Clinical Medicine, 2020, 9, 332.	2.4	2
34	Severity of Megakaryocyte-Driven Osteosclerosis in Mpig6b-Deficient Mice Is Sex-Linked. Journal of Bone and Mineral Research, 2020, 36, 803-813.	2.8	9
35	Effects of reading media on reading comprehension in health professional education: a systematic review protocol. JBI Evidence Synthesis, 2020, 18, 2633-2639.	1.3	1
36	ASSOCIATION OF PLATELET ACTIVITY WITH CIRCULATING LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND COGNITIVE FUNCTION: A CROSS-SECTIONAL STUDY. Canadian Journal of Cardiology, 2019, 35, S122.	1.7	0

#	ARTICLE	IF	CITATIONS
37	EFFECT OF LOSARTAN ON PLATELET RESPONSES TO CLASSIC AGONISTS. Canadian Journal of Cardiology, 2019, 35, S26.	1.7	0
38	LARGE-SCALE ASSESSMENT OF PLATELET DIFFERENTIAL SECRETION. Canadian Journal of Cardiology, 2019, 35, S127-S128.	1.7	0
39	Platelet Function in Aging. Frontiers in Cardiovascular Medicine, 2019, 6, 109.	2.4	61
40	Clinical Tests of Platelet Function. , 2019, , 593-608.		1
41	750. Critical Care Medicine, 2019, 47, 354.	0.9	0
42	Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study. Thrombosis Research, 2019, 174, 48-50.	1.7	4
43	Increased platelet reactivity and plateletâ€œleukocyte aggregation after elective coronary bypass surgery. Platelets, 2019, 30, 975-981.	2.3	12
44	Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis. Platelets, 2019, 30, 817-827.	2.3	1
45	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y<sub>12</sub> receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 543-553.	1.0	15
46	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	1.7	181
47	Platelets at the heart of therapy. Platelets, 2018, 29, 103-104.	2.3	0
48	Personalizing antiplatelet therapies: What have we learned from recent trials?. Platelets, 2018, 29, 131-139.	2.3	8
49	An interview with Professor Gus Born. Platelets, 2018, 29, 744-748.	2.3	1
50	Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	1.0	53
51	Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 823-835.	2.4	28
52	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thrombosis Research, 2017, 149, 64-69.	1.7	12
53	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. Journal of Thoracic Disease, 2017, 9, E440-E443.	1.4	2
54	Platelet Function Tests. , 2017, , 559-570.		2

#	ARTICLE	IF	CITATIONS
55	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 905-910.	3.4	5
56	Platelet Function Tests. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 258-267.	2.7	57
57	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. <i>Haematologica</i> , 2016, 101, 1170-1179.	3.5	119
58	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY. <i>Canadian Journal of Cardiology</i> , 2016, 32, S118-S119.	1.7	0
59	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY. <i>Canadian Journal of Cardiology</i> , 2016, 32, S252.	1.7	0
60	The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 500-512.	4.7	13
61	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. <i>Biomarkers in Medicine</i> , 2016, 10, 903-918.	1.4	8
62	Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?. <i>Thrombosis Research</i> , 2015, 136, 1057-1058.	1.7	1
63	Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 88.	5.3	7
64	Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. <i>Thrombosis and Haemostasis</i> , 2015, 113, 826-837.	3.4	15
65	Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 643-650.	3.8	63
66	The role of platelets in the recruitment of leukocytes during vascular disease. <i>Platelets</i> , 2015, 26, 507-520.	2.3	146
67	Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease. <i>Platelets</i> , 2015, 26, 545-551.	2.3	7
68	SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. <i>Journal of Clinical Investigation</i> , 2015, 125, 3600-3605.	8.2	71
69	The prognostic utility of tests of platelet function for the detection of "aspirin resistance"™ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-366.	2.8	22
70	A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction. <i>Thrombosis and Haemostasis</i> , 2014, 112, 923-932.	3.4	19
71	Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. <i>Systematic Reviews</i> , 2014, 3, 140.	5.3	19
72	Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 660-665.	3.8	40

#	ARTICLE	IF	CITATIONS
73	A novel mutation in the P2Y <sub>12</sub> receptor and a function-reducing polymorphism in protease-activated receptor-1 in a patient with chronic bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 716-725.	3.8	40
74	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. <i>Blood</i> , 2014, 123, e11-e22.	1.4	60
75	Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. <i>Systematic Reviews</i> , 2013, 2, 16.	5.3	5
76	Genotyping and phenotyping of platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 351-363.	3.8	62
77	Testing Platelet Function. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 411-441.	2.2	52
78	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1627-1639.	3.8	28
79	Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. <i>Blood</i> , 2013, 122, 4090-4093.	1.4	108
80	OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia. <i>Thrombosis Research</i> , 2013, 131, S74.	1.7	1
81	Clinical Tests of Platelet Function. , 2013, , 519-545.		9
82	Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1663-1668.	3.8	103
83	Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life. <i>Thrombosis and Haemostasis</i> , 2013, 109, 766-768.	3.4	22
84	Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine. <i>Thrombosis and Haemostasis</i> , 2013, 110, 199-201.	3.4	6
85	Platelet Turnover in Atherothrombotic Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5328-5343.	1.9	20
86	Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. <i>Blood</i> , 2012, 120, 5041-5049.	1.4	92
87	50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. <i>Platelets</i> , 2012, 23, 415-422.	2.3	40
88	Advances in monitoring of aspirin therapy. <i>Platelets</i> , 2012, 23, 526-536.	2.3	35
89	Aspirin twice a day keeps new COX-1 at bay. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1217-1219.	3.8	20
90	G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes. <i>PLoS ONE</i> , 2012, 7, e52622.	2.5	9

#	ARTICLE	IF	CITATIONS
91	Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. International Journal of Cardiology, 2011, 150, 39-44.	1.7	31
92	Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thrombosis Research, 2011, 128, 47-53.	1.7	32
93	Beware of being caught on the rebound. Journal of Thrombosis and Haemostasis, 2011, 9, 21-23.	3.8	9
94	Why an aspirin a day no longer keeps the doctor away â€¦. Thrombosis and Haemostasis, 2011, 105, 209-210.	3.4	13
95	Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. International Journal of Cardiology, 2010, 143, 43-50.	1.7	21
96	Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. , 2009, 123, 178-186.		75
97	Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease. American Journal of Cardiology, 2009, 104, 1189-1193.	1.6	14
98	Weekâ€‘Long Highâ€‘Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Doubleâ€‘Blind, Randomized Clinical Trial. Journal of Interventional Cardiology, 2009, 22, 368-377.	1.2	7
99	Evaluation of the platelet count drop method for assessment of platelet function in comparison with â€‘gold standardâ€‘ light transmission aggregometry. Thrombosis Research, 2009, 124, 418-422.	1.7	17
100	Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thrombosis Research, 2009, 124, 546-553.	1.7	16
101	Response to aspirin in healthy individuals. Thrombosis and Haemostasis, 2009, 102, 404-411.	3.4	66
102	Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. European Heart Journal, 2008, 29, 2877-2885.	2.2	133
103	Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition. Therapeutic Drug Monitoring, 2008, 30, 372-378.	2.0	36
104	Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply. European Heart Journal, 2007, 29, 138-139.	2.2	1
105	A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. European Heart Journal, 2007, 28, 1702-1708.	2.2	465
106	Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNowâ„¢ System, Platelet Count Drop, Thrombelastography (TEGâ„®) and Urinary 11-dehydrothromboxane B2.. Blood, 2007, 110, 934-934.	1.4	0
107	Aspirin resistance: Truth or dare. , 2006, 112, 733-743.		39